Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Overview of attention for article published in New England Journal of Medicine, September 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

So far, Altmetric has seen 4 public wall posts from 3 users.

Thank you to Violet for sharing this with us to pass along to you, omies. ⬇️ #esmo22 Dear all, we (Koen, Martina and I…

Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients…

Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients…

Original Article from The New England Journal of Medicine — Overall Survival Benefit with Tebentafusp in Metastatic Uveal…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity.